Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, HIV Research and Treatment, and HIV-related health complications and treatments.
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Social Media Savvy, It's More Than Just the #Hashtags: How the Use of Social Media in Transplant Infectious Diseases Can Impact the Field and Patients.
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel
Antiretrovirals and Weight Change: Weighing the Evidence.
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse
Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.
Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals.
Long-Acting Cabotegravir Plus Rilpivirine in People With HIV With Adherence Challenges and Viremia: Current Data and Future Directions
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy.
Incidence of Symptoms Associated with Post-Acute Sequelae of SARS-CoV-2 infection in Non-Hospitalized Vaccinated Patients Receiving Nirmatrelvir-Ritonavir
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Two-drug regimens for HIV treatment
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Clinical and Economic Impact of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission
Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
Gender disparities in international COVID-19 clinical trial leadership
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202
Middle-Aged Men With HIV Have Diminished Accelerometry-Based Activity Profiles Despite Similar Lab-Measured Gait Speed: Pilot Study.
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Generalizing Evidence from Randomized Trials Using Inverse Probability of Sampling Weights
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353